Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Summit Therapeutics Inc. SMMT
$1.79
-$0.13 (-7.27%)
На 18:01, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
1353299579.00000000
-
week52high
5.78
-
week52low
0.66
-
Revenue
704295
-
P/E TTM
-5
-
Beta
-1.01591600
-
EPS
-0.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SunTrust Robinson Humphrey | Hold | Buy | 25 ноя 2020 г. |
| Janney Capital | Neutral | Buy | 25 ноя 2020 г. |
| H.C. Wainwright | Buy | 25 ноя 2020 г. | |
| HC Wainwright & Co. | Neutral | Buy | 18 ноя 2020 г. |
| H.C. Wainwright | Buy | 19 мар 2020 г. | |
| HC Wainwright & Co. | Buy | 19 мар 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Booth Robert F. | A | 67700 | 32700 | 03 янв 2023 г. |
| Booth Robert F. | A | 35000 | 35000 | 03 янв 2023 г. |
| Cesano Alessandra | A | 51350 | 16350 | 03 янв 2023 г. |
| Cesano Alessandra | A | 35000 | 35000 | 03 янв 2023 г. |
| Mahatme Ujwala | A | 75500 | 40500 | 03 янв 2023 г. |
| Mahatme Ujwala | A | 35000 | 35000 | 03 янв 2023 г. |
| Soni Manmeet Singh | A | 35000 | 35000 | 03 янв 2023 г. |
| Clark Kenneth A | A | 79400 | 44400 | 03 янв 2023 г. |
| Clark Kenneth A | A | 35000 | 35000 | 03 янв 2023 г. |
| Zanganeh Mahkam | A | 10930849 | 373857 | 06 дек 2022 г. |
Новостная лента
Why Shares of Summit Therapeutics Soared This Week
The Motley Fool
05 мая 2023 г. в 17:08
The company's current pipeline only includes two drugs. Summit Therapeutics' shares are up more than 93% over the past 12 months.
Strong Small-Cap Insider Buys: Q1 2023
Seeking Alpha
26 апр 2023 г. в 00:15
Strong Small-Cap Insider Buys: Q1 2023.
Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere
Seeking Alpha
13 апр 2023 г. в 10:49
Summit Therapeutics is mostly owned by Bob Duggan, who made billions from selling Pharmacyclics. However, Pharmacyclics had something to sell.
Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript
Seeking Alpha
10 мар 2023 г. в 18:43
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q4 2022 Results Conference Call March 9, 2023 9:00 AM ET Company Participants Dave Gancarz - SVP, Corporate Strategy and Stakeholder Relations Dr. Maky Zanganeh - Co-CEO and President Bob Duggan - Chairman and CEO Ankur Dhingra - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your conference operator today.
Summit Therapeutics: Ivonescimab Deal Potential Mid-Term Growth Driver
Seeking Alpha
27 янв 2023 г. в 10:00
Summit Therapeutics rallied hard off 52-week lows in December after its licensing deal for Ivonescimab was announced. Gains have extended into the new year, which is promising for those seeking to enter long at the current market value.